ArticleScience translational medicine2019
Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity.
Abstract read
In one paragraph
Article in Science translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Cytomegalovirus latency-the sum of subtleties.Journal of virology · 2025Review
- Glycoprotein L-deleted single-cycle rhesus cytomegalovirus vectors elicit MHC-E-restricted CD8+ T cells that protect against SIV.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Exploitation of Unconventional CD8 T-Cell Responses Induced by Engineered Cytomegaloviruses for the Development of an HIV-1 Vaccine.Vaccines · 2025Review
- Brain virome dysbiosis in Parkinson's disease and multiple system atrophy.Frontiers in microbiology · 2025Article
- Heightened innate immune state induced by viral vector leads to enhanced response to challenge and prolongs malaria vaccine protection.iScience · 2024Article
- Functional genomic analysis of the 68-1 RhCMV-Frontiers in immunology · 2024Article
- Programming cytomegalovirus as an HIV vaccine.Trends in immunology · 2023Review
- Late gene expression-deficient cytomegalovirus vectors elicit conventional T cells that do not protect against SIV.JCI insight · 2023Article
- Alternative splicing and genetic variation of mhc-e: implications for rhesus cytomegalovirus-based vaccines.Communications biology · 2022Article
- Endothelial Cell Infection by Guinea Pig Cytomegalovirus Is a Lytic or Persistent Infection Depending on Tissue Origin but Requires Viral Pentamer Complex and pp65 Tegument Protein.Journal of virology · 2022Article
- Article
- Myeloid cell tropism enables MHC-E-restricted CD8Science immunology · 2022Article
- Cytomegalovirus mediates expansion of IL-15-responsive innate-memory cells with SIV killing function.The Journal of clinical investigation · 2021Article
- Guinea pig cytomegalovirus protective T cell antigen GP83 is a functional pp65 homolog for innate immune evasion and pentamer dependent virus tropism.Journal of virology · 2021Article
- In vitro and in vivo characterization of a recombinant rhesus cytomegalovirus containing a complete genome.PLoS pathogens · 2020Article
- MHC-E-Restricted CD8Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Novel Strategies to Combat CMV-Related Cardiovascular Disease.Pathogens & immunity · 2020Review
- Expanding the Known Functional Repertoire of the Human Cytomegalovirus pp71 Protein.Frontiers in cellular and infection microbiology · 2020Review
- Characterization of a live-attenuated HCMV-based vaccine platform.Scientific reports · 2019Article
- Vaccine Vectors Harnessing the Power of Cytomegaloviruses.Vaccines · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 2 institutions in 1 country.
Emily E MarshallVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID 0000-0003-4049-8934
Daniel MalouliVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID 0000-0003-1287-7283
Scott G HansenVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-9845-6481
Roxanne M GilbrideVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
Colette M HughesVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
Abigail B VenturaVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
Emily AinslieVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-3734-7142
Andrea N SelsethVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
Julia C FordVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-4989-2842
David BurkeVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
Craig N KreklywichVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
Jennie WomackVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-4941-3696
Alfred W LegasseVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-4618-7873
Michael K AxthelmVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-1984-5906
Christoph KahlVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-9370-5928
Daniel StreblowVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.
Paul T EdlefsenStatistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0002-8393-8103
Louis J PickerVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA. pickerl@ohsu.edu fruehk@ohsu.edu.ORCID 0000-0003-0546-398X
Klaus FrühVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA. pickerl@ohsu.edu fruehk@ohsu.edu.ORCID 0000-0001-8014-3877
Oregon National Primate Research Center · USFred Hutch Cancer Center · US
Funding
Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9MVirology CoreP01AI129859 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Sallie R. Permar · 2019 to 2026
$31.0MPhase 2 Enhancement of Outdoor Group Housing for U42 SPF 9 Rhesus MacaquesU42OD023038 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Andrew Haertel · 2016 to 2026
$21.9MVirology and Immunology MonitoringP01AI094417 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI PICKER, LOUIS J. · 2011 to 2016
$20.5MVirology and Vector Production Core CU19AI128741 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI STREBLOW, DANIEL N · 2017 to 2021
$11.8MRole of Memory T Cell Dynamics in SIV InfectionR37AI054292 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI PICKER, LOUIS J. · 2008 to 2017
$9.8MEvasion of Antigen Presentation by Rhesus CytomegalovirusR01AI059457 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI FRUH, KLAUS J · 2005 to 2021
$6.2MViral Testing CoreU42OD010426 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Andrew Haertel, Lauren Drew Martin · 2013 to 2026
$6.0MDevelopment and In Vivo Characterization of Safety-Enhanced RhCMV/SIV VectorsR01AI095113 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI PICKER, LOUIS J. · 2011 to 2015
$4.1MRole of memory T cell dynamics in SIV infectionR01AI054292 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI PICKER, LOUIS J. · 2003 to 2007
$3.7MNon-canonical epitope presentation and antigen processing by MHC-ER01AI175459 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Klaus J Fruh, Jonah B. Sacha · 2023 to 2026
$2.8MNIAID NIH HHS P01 AI094417NIAID NIH HHS P01 AI129859NIAID NIH HHS R01 AI054292NIAID NIH HHS R01 AI059457NIAID NIH HHS R01 AI095113NIAID NIH HHS R01 AI175459NIAID NIH HHS R37 AI054292NIAID NIH HHS U19 AI128741NIH HHS P51 OD011092NIH HHS U42 OD010426NIH HHS U42 OD023038
Abstract
Rhesus cytomegalovirus (RhCMV)-based vaccines maintain effector memory T cell responses (T
Indexed as
ImmunityAnimalsCo-Repressor ProteinsCytomegalovirusCytomegalovirus VaccinesGene DeletionGenetic VectorsLeukocytesMacaca mulattaProteolysisRecombination, GeneticT-LymphocytesViral ProteinsCo-Repressor Proteinscytomegalovirus phosphoprotein 71kDaCytomegalovirus VaccinesViral Proteins
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.